Updated:
Renold Pension
Incorporated in March 2013, Renold Pensions Limited operates as the non-trading corporate trustee for the pension obligations of Renold Plc, a publicly listed...
Renold Pension
Incorporated in March 2013, Renold Pensions Limited operates as the non-trading corporate trustee for the pension obligations of Renold Plc, a publicly listed manufacturer headquartered in Manchester. The fund exists to meet the retirement promises made to the UK workforce of Renold's industrial power-transmission business. Its governance is closely tied to the sponsoring employer's leadership — Renold Plc's chairman and CEO serve as trustee directors, blurring the line between corporate treasury and fiduciary duty. As a defined-benefit pension scheme typical of legacy UK industrial employers, Renold's strategy centers on liability-driven investment, with a marked emphasis on de-risking. A medically underwritten pensioner buy-in policy — a bulk annuity transaction that covers a specific tranche of retiree liabilities — is one of the scheme's only publicly known assets. The fund does not market itself to external investors, publish portfolio composition, or disclose participation in direct private investments, growth equity, or venture capital. Its investment activity appears confined to securing the insurance wrapper around pensioner cashflows, a posture that places it in the endgame phase of the UK defined-benefit life cycle. The scheme's scale remains undisclosed, and no recent asset manager mandates, alternative allocations, or co-investment structures have surfaced through public disclosures. Renold Pensions Limited itself is an administrative shell — no dedicated investment team is listed outside the trustee directors drawn from the operating company. The parent, Renold Plc, engages Ares Management Corporation for corporate financing and MPE as its private equity acquirer, but there is no evidence those relationships extend into pension asset management. What distinguishes this scheme is the accelerating completion of its pension de-risking journey under the shadow of an ownership change. MPE's memorandum of understanding with the trustee regarding pension funding — a condition of the 2025 acquisition of Renold Plc — signals that the fund's ultimate structure and capitalization were negotiated directly with a well-known private equity buyer. That places Renold Pension in the cohort of legacy sponsor schemes where a corporate transaction becomes the catalyst for a final liability settlement.
General information
Firm type
Pension Fund
Year founded
2013
Location
Region
Europe
Country
United Kingdom
City
Manchester
Corporate office
Manchester, United Kingdom
Principals
David Landless
Chairman of Renold Plc and Trustee/Director
Robert Purcell
Chief Executive of Renold Plc
Sector focus
Frequently asked questions
Who runs investment decisions at the Renold Pension Scheme?
Investment decisions fall to the trustee board of Renold Pensions Limited. Its known directors are Renold Plc Chairman David Landless and CEO Robert Purcell, who wear both corporate and fiduciary hats. The trustee structure follows standard UK corporate pension governance: operating-company executives sit alongside any independent professional trustees the scheme may retain, but no separate investment office or CIO has been publicly identified.
Is the Renold Pension Scheme structured as a family office?
No. It is a corporate defined-benefit pension scheme — an asset owner that holds retirement assets for current and former employees of Renold Plc, the industrial chain and gear manufacturer. The scheme has no wealth management, multi-generational planning, or direct private-investment mandate for a family, and it does not operate like a single- or multi-family office.
Does the scheme participate in fund commitments or direct deals?
There is no public evidence of fund commitments, co-investments, venture allocations, or direct private-market deals. The only disclosed transaction is a medically underwritten pensioner buy-in — a bulk annuity contract purchased from a UK insurer — which signals a pure liability-hedging posture rather than a return-seeking investment program.
How did the MPE acquisition of Renold Plc affect the pension scheme?
The 2025 acquisition by MPE included a memorandum of understanding between the buyer, Renold Plc, and the pension trustee that addressed post-transaction funding. Such agreements are common when a private equity sponsor assumes a defined-benefit obligation: they typically set future contribution schedules, potential lump-sum injections, or a path toward a full buy-out. The specific terms remain confidential, but the existence of a negotiated MoU suggests the scheme's funding status was material to the deal.
What is a medically underwritten pensioner buy-in, and why does the scheme hold one?
A medically underwritten buy-in is a bulk annuity contract where the insurer prices coverage using individual health assessments of pensioner members — those in poorer health receive lower-cost coverage, reducing the overall premium. For the Renold scheme, entering such a buy-in means the trustee has irrevocably transferred a slice of pensioner liabilities to an insurance company, a step that reduces longevity and investment risk on the scheme's books. It is a common tactic for UK schemes approaching full buy-out.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on pension funds?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: